对T2低喘的诊断和治疗选择
Dennis Thomas1, Yuto Hamada2, Peter Gibson3
1Center of Excellence in Treatable Traits, College of Health, Medicine and Wellbeing, University of Newcastle, New Lambton Heights, NSW, Australia; Asthma and Breathing Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.
概括
2型低喘,缺乏乙酸性炎症,存在诊断方面的挑战. 管理包括解决肥胖和并发病症,而阿齐思罗米辛在不受控制的情况下显示出缓解的希望.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 喘研究 喘研究
背景情况:
- 2型低喘缺少T2介导的叶氨酸性气道炎症.
- 由于缺乏特定的生物标志物和皮质类固醇干扰,诊断是复杂的.
- 肥胖是一种重要的并发症,有助于T2低喘负担.
研究的目的:
- 审查2型低喘的特征,挑战和新兴治疗方法.
- 突出T2-低喘的流行率和表型变异.
- 讨论当前和未来的治疗策略.
主要方法:
- 对T2低喘特征,生物标志物和治疗结果的文献综述.
- 对T2低喘表型的分析,包括与肥胖相关的和中性友好的亚型.
- 评估当前的管理策略和新的治疗目标.
主要成果:
- 低T2喘的表型包括晚发,与衰老相关,与肥胖相关,中性恋性和paucigranulocytic.
- 亚齐思罗米在未经控制的T2低喘患者中显示出高达50%的临床缓解的潜力.
- 严重的T2-低喘中的恶化可能会转变为T2-高喘,长期预后不清楚.
结论:
- 有效的管理需要解决并发症,优化皮质类固醇,并探索添加治疗方法,如阿齐思罗米.
- 准微生物失生症和探索IL33通路的生物药物是有希望的未来方向.
- 进一步的研究对于优化各种T2低喘表型的管理策略至关重要.
相关概念视频
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
COPD: Management Using Bronchodilators and Corticosteroids
148
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
148
Drugs Used in Lower Respiratory Disorders: Overview
284
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
284
Antiasthma Drugs: Leukotriene Modifiers
180
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
180
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
186
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
186


